Literature DB >> 10931589

MRI with mangafodipir trisodium in the detection and staging of pancreatic cancer.

M G Romijn1, J Stoker, C H van Eijck, J M van Muiswinkel, C G Torres, J S Laméris.   

Abstract

The purpose of this study was to compare prospectively computed tomography (CT) and magnetic resonance (MR) imaging before and after mangafodipir trisodium infusion for the detection and staging of focal pancreatic lesions. From November 1996 to October 1997, 43 consecutive patients suspected to have a focal pancreatic lesion were included in a phase III study. Triphasic helical CT was performed, as well as MRI at 1.5 T, as follows: axial T1-weighted (T1w) turbo spin echo (TSE), spectral presaturation with inversion recovery (SPIR) T1w TSE, T1w turbo field echo (TFE), and SPIR T2w TSE before and after mangafodipir trisodium (0.01 mmol/ml, 0.5 ml/kg) infusion. Imaging results were correlated with surgery, laparoscopy, laparoscopic ultrasound, and biopsy. Objective measurements were performed by measuring signal intensities (SIs) of lesion and parenchyma and calculating contrast indexes (CIs) and contrast-to-noise-ratios (CNRs) to assess the delineation of the tumor. SIs were correlated with four phantom standards with a known SI. Thirty-eight pancreatic adenocarcinomas were present, as well as one cystadenoma, two papillomas, and two cases of focal pancreatitis. SI measurements revealed significant increases in CIs for the lesion compared with the parenchyma in T1w TSE (69.7 vs 152.7; P = 0. 0003) and T1w TFE (107.8 vs 194.2; P = 0.0002). These series also revealed significant increases in CNRs (for T1w TSE: 9.7 vs 13.0; P = 0.0407 and for T1w TFE: 14.5 vs 26.1; P = 0.0001). In the other series, there was no significant increase. CT detected 38 lesions, MRI without mangafodipir trisodium detected 39 lesions, and MRI with mangafodipir trisodium detected 40 lesions, giving detection accuracy rates of 88%, 91%, and 93%, respectively. Staging accuracy rates for vascular ingrowth were 81%, 75%, and 81%, respectively. Overall staging accuracy rates were 57%, 54%, and 54%, respectively, mostly due to undetected small metastases in the peritoneum, omentum, or liver (< 1 cm). This study indicates that a) MRI after mangafodipir trisodium gives a better delineation of the tumor in T1w series, but b) does not significantly improve the detection rate and staging accuracy of focal pancreatic lesions over MRI without this contrast medium.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10931589     DOI: 10.1002/1522-2586(200008)12:2<261::aid-jmri8>3.0.co;2-r

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  12 in total

Review 1.  Diagnostic accuracy of different imaging modalities following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer.

Authors:  Domenico Tamburrino; Deniece Riviere; Mohammad Yaghoobi; Brian R Davidson; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2016-09-15

Review 2.  Pancreatic adenocarcinoma.

Authors:  Wolfgang Schima; Ahmed Ba-Ssalamah; Claus Kölblinger; Christiane Kulinna-Cosentini; Andreas Puespoek; Peter Götzinger
Journal:  Eur Radiol       Date:  2006-10-05       Impact factor: 5.315

Review 3.  Vascular invasion in pancreatic cancer: Imaging modalities, preoperative diagnosis and surgical management.

Authors:  Nicolas C Buchs; Michael Chilcott; Pierre-Alexandre Poletti; Leo H Buhler; Philippe Morel
Journal:  World J Gastroenterol       Date:  2010-02-21       Impact factor: 5.742

4.  Mangafodipir trisodium-enhanced magnetic resonance imaging for evaluation of pancreatic mass and mass-like lesions.

Authors:  Gul Eser; Aydin Karabacakoglu; Serdar Karakose; Cengiz Eser; Ertugrul Kayacetin
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

Review 5.  Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010.

Authors:  Chakshu Sharma; Karim M Eltawil; Paul D Renfrew; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

6.  Mangafodipir trisodium-enhanced MR imaging of pancreatic disease.

Authors:  Piero Boraschi; Francescamaria Donati; Roberto Gigoni; Davide Caramella; Ugo Boggi; Fabio Falaschi; Carlo Bartolozzi
Journal:  Eur Radiol       Date:  2006-01-19       Impact factor: 5.315

Review 7.  [Pancreas. Part II: Tumors].

Authors:  W Schima; A Ba-Ssalamah; C Plank; C Kulinna-Cosentini; R Prokesch; B Tribl; T Sautner; B Niederle
Journal:  Radiologe       Date:  2006-05       Impact factor: 0.635

8.  Diagnosis of pancreatic cancer.

Authors:  Fumihiko Miura; Tadahiro Takada; Hodaka Amano; Masahiro Yoshida; Shigeru Furui; Koji Takeshita
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

9.  Liver blood supply after a modified Appleby procedure in classical and aberrant arterial anatomy.

Authors:  Vyacheslav I Egorov; Roman V Petrov; Michail V Lozhkin; Olga A Maynovskaya; Natalia S Starostina; Natalia R Chernaya; Ekaterina M Filippova
Journal:  World J Gastrointest Surg       Date:  2013-03-27

Review 10.  Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.

Authors:  Peter Reimer; Günter Schneider; Wolfgang Schima
Journal:  Eur Radiol       Date:  2004-02-25       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.